These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20656008)

  • 1. Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project.
    Gómez-Lechón MJ; Tolosa L; Castell JV; Donato MT
    Toxicol In Vitro; 2010 Oct; 24(7):1879-89. PubMed ID: 20656008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of potential hepatotoxicity induced by drugs.
    Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
    Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity.
    Van Summeren A; Renes J; van Delft JH; Kleinjans JC; Mariman EC
    Toxicol In Vitro; 2012 Apr; 26(3):373-85. PubMed ID: 22274661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity.
    He JH; Guo SY; Zhu F; Zhu JJ; Chen YX; Huang CJ; Gao JM; Dong QX; Xuan YX; Li CQ
    J Pharmacol Toxicol Methods; 2013; 67(1):25-32. PubMed ID: 23128142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of hepatocytes to investigate drug toxicity.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Methods Mol Biol; 2010; 640():389-415. PubMed ID: 20645064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity assay using human hepatocytes trapped in microholes of a microfluidic device.
    Yeon JH; Na D; Park JK
    Electrophoresis; 2010 Sep; 31(18):3167-74. PubMed ID: 20872616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates?
    Mesens N; Crawford AD; Menke A; Hung PD; Van Goethem F; Nuyts R; Hansen E; Wolterbeek A; Van Gompel J; De Witte P; Esguerra CV
    J Appl Toxicol; 2015 Sep; 35(9):1017-29. PubMed ID: 25663337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development.
    Blomme EA; Yang Y; Waring JF
    Toxicol Lett; 2009 Apr; 186(1):22-31. PubMed ID: 18996174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.
    Giri S; Nieber K; Bader A
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.
    Weaver RJ; Betts C; Blomme EAG; Gerets HHJ; Gjervig Jensen K; Hewitt PG; Juhila S; Labbe G; Liguori MJ; Mesens N; Ogese MO; Persson M; Snoeys J; Stevens JL; Walker T; Park BK
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):767-782. PubMed ID: 28604124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivities of gel entrapped hepatocytes in hollow fibers to hepatotoxic drug.
    Meng Q; Zhang G; Shen C; Qiu H
    Toxicol Lett; 2006 Sep; 166(1):19-26. PubMed ID: 16814964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-content screening technology for studying drug-induced hepatotoxicity in cell models.
    Tolosa L; Gómez-Lechón MJ; Donato MT
    Arch Toxicol; 2015 Jul; 89(7):1007-22. PubMed ID: 25787152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatotoxic effects of drugs from some pharmacological groups].
    Kinzirskaia IuA; Bogush TA; Ostapchuk NV; Fisenko VP
    Klin Med (Mosk); 2003; 81(10):11-6. PubMed ID: 14664165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved.
    Martínez-Sena T; Moro E; Moreno-Torres M; Quintás G; Hengstler J; Castell JV
    Arch Toxicol; 2023 Jun; 97(6):1723-1738. PubMed ID: 37022445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-Driven Read-Across of Chemical Hepatotoxicants Based on Chemical Structures and Biological Data.
    Zhao L; Russo DP; Wang W; Aleksunes LM; Zhu H
    Toxicol Sci; 2020 Apr; 174(2):178-188. PubMed ID: 32073637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BK/TD models for analyzing in vitro impedance data on cytotoxicity.
    Teng S; Barcellini-Couget S; Beaudouin R; Brochot C; Desousa G; Rahmani R; Pery AR
    Toxicol Lett; 2015 Jun; 235(2):96-106. PubMed ID: 25827406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overtaking the DILI Model-T.
    Opar A
    Nat Rev Drug Discov; 2012 Aug; 11(8):585-6. PubMed ID: 22850771
    [No Abstract]   [Full Text] [Related]  

  • 19. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.
    Bauman JN; Kelly JM; Tripathy S; Zhao SX; Lam WW; Kalgutkar AS; Obach RS
    Chem Res Toxicol; 2009 Feb; 22(2):332-40. PubMed ID: 19161298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.